Rifaximin, Microbiota Biology, and Hepatic Encephalopathy

Cedric Peleman; Michael Camilleri

doi:10.1038/ctg.2016.52

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy

Cedric Peleman, Michael Camilleri

Gastroenterology and Hepatology

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Rifaximin is beneficial in the treatment of minimal hepatic encephalopathy (MHE). Kang et al. (Clin Transl Gastroenterol 7: e187; doi:10.1038/ctg.2016.44) investigated the effects of rifaximin in a mouse model of MHE-associated microbiota without concomitant liver disease. In addition to some impact on the composition of microbiota, rifaximin altered bacterial functions, ameliorated local and systemic inflammation, and reduced enterocyte glutaminase activity. We discuss these effects as well as the interpretation of the permeability studies, given the potential interaction of dysbiosis with dysfunctional intestinal barrier, leading to systemic inflammation and increased uptake of bacterial metabolites that contribute to MHE in the presence of hepatic dysfunction.

Original language	English (US)
Article number	e195
Journal	Clinical and translational gastroenterology
Volume	7
Issue number	10
DOIs	https://doi.org/10.1038/ctg.2016.52
State	Published - Oct 6 2016

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1038/ctg.2016.52

Cite this

@article{afec89bb07df4170b35f7e0f8e9f1d93,

title = "Rifaximin, Microbiota Biology, and Hepatic Encephalopathy",

abstract = "Rifaximin is beneficial in the treatment of minimal hepatic encephalopathy (MHE). Kang et al. (Clin Transl Gastroenterol 7: e187; doi:10.1038/ctg.2016.44) investigated the effects of rifaximin in a mouse model of MHE-associated microbiota without concomitant liver disease. In addition to some impact on the composition of microbiota, rifaximin altered bacterial functions, ameliorated local and systemic inflammation, and reduced enterocyte glutaminase activity. We discuss these effects as well as the interpretation of the permeability studies, given the potential interaction of dysbiosis with dysfunctional intestinal barrier, leading to systemic inflammation and increased uptake of bacterial metabolites that contribute to MHE in the presence of hepatic dysfunction.",

author = "Cedric Peleman and Michael Camilleri",

note = "Publisher Copyright: {\textcopyright} 2016 the American College of Gastroenterology.",

year = "2016",

month = oct,

day = "6",

doi = "10.1038/ctg.2016.52",

language = "English (US)",

volume = "7",

journal = "Clinical and translational gastroenterology",

issn = "2155-384X",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Rifaximin, Microbiota Biology, and Hepatic Encephalopathy

AU - Peleman, Cedric

AU - Camilleri, Michael

PY - 2016/10/6

Y1 - 2016/10/6

N2 - Rifaximin is beneficial in the treatment of minimal hepatic encephalopathy (MHE). Kang et al. (Clin Transl Gastroenterol 7: e187; doi:10.1038/ctg.2016.44) investigated the effects of rifaximin in a mouse model of MHE-associated microbiota without concomitant liver disease. In addition to some impact on the composition of microbiota, rifaximin altered bacterial functions, ameliorated local and systemic inflammation, and reduced enterocyte glutaminase activity. We discuss these effects as well as the interpretation of the permeability studies, given the potential interaction of dysbiosis with dysfunctional intestinal barrier, leading to systemic inflammation and increased uptake of bacterial metabolites that contribute to MHE in the presence of hepatic dysfunction.

AB - Rifaximin is beneficial in the treatment of minimal hepatic encephalopathy (MHE). Kang et al. (Clin Transl Gastroenterol 7: e187; doi:10.1038/ctg.2016.44) investigated the effects of rifaximin in a mouse model of MHE-associated microbiota without concomitant liver disease. In addition to some impact on the composition of microbiota, rifaximin altered bacterial functions, ameliorated local and systemic inflammation, and reduced enterocyte glutaminase activity. We discuss these effects as well as the interpretation of the permeability studies, given the potential interaction of dysbiosis with dysfunctional intestinal barrier, leading to systemic inflammation and increased uptake of bacterial metabolites that contribute to MHE in the presence of hepatic dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=84990198040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990198040&partnerID=8YFLogxK

U2 - 10.1038/ctg.2016.52

DO - 10.1038/ctg.2016.52

M3 - Review article

AN - SCOPUS:84990198040

SN - 2155-384X

VL - 7

JO - Clinical and translational gastroenterology

JF - Clinical and translational gastroenterology

IS - 10

M1 - e195

ER -

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this